Tag: cannabidiol

🧪 Exciting Breakthrough in Cannabis Use Disorder Treatment!

A recent Phase 2b clinical trial has shown that PP-01, an investigational therapy by PleoPharma, significantly reduces cannabis withdrawal symptoms in individuals with Cannabis Use Disorder (CUD). The study demonstrated a clear dose-response relationship, with the highest dose yielding clinically meaningful results (p=0.02). Importantly, PP-01 was well-tolerated with no safety concerns.

Recognizing the urgent need for effective treatments, the FDA has granted Fast Track designation to PP-01, expediting its development and review process. This brings hope to the approximately 19.2 million Americans affected by CUD, as there are currently no FDA-approved medications for cannabis withdrawal.

PP-01 works by targeting suppressed CB1 receptors and neurotransmitter dysregulation in the brain’s reward pathway, offering a novel approach to mitigating withdrawal symptoms. As it enters Phase 3 trials, PP-01 holds promise as a first-in-class treatment for those seeking to overcome cannabis dependence.

0

🚨 New JAMA Study: Cannabis Legalization & Schizophrenia

A groundbreaking study just dropped in JAMA Psychiatry, shedding light on the link between cannabis use disorder (CUD) and schizophrenia following cannabis legalization.

📊 Key Findings:

  • Higher rates of schizophrenia diagnoses were observed in young men with CUD after legalization.
  • The association was strongest in males aged 18–24, a group already at high risk for schizophrenia onset.
  • No significant changes were found in individuals without CUD, reinforcing concerns about cannabis as a potential trigger in vulnerable populations.

🧠 What This Means:
Cannabis legalization doesn’t just increase access—it may be shifting the trajectory of severe mental illness in at-risk groups. While correlation ≠ causation, this study adds weight to the argument that heavy cannabis use isn’t harmless, especially for young people with genetic or neurodevelopmental vulnerabilities.

⚖️ Clinical & Policy Implications:

  • Should we rethink cannabis policy in light of these findings?
  • Do we need stronger public health messaging about the psychiatric risks of heavy cannabis use?
  • How can we better screen and intervene early for CUD in young men?

As psychiatrists, we see these cases firsthand—the young man with new-onset psychosis, the family blindsided, the struggle to regain lost cognitive and social function.

This study is a wake-up call. Legal ≠ safe for everyone.

What are your thoughts? Should legalization come with more psychiatric safeguards? Drop your insights below. ⬇️

0

🚨 New Study: Cannabis Use Disorder Linked to 3X Higher Mortality in Hospital & ER Patients

A major new study has uncovered a staggering risk: Patients diagnosed with Cannabis Use Disorder (CUD) in hospitals or ERs had nearly THREE TIMES the mortality rate over the next five years compared to those without the disorder.

🔎 Key Findings:

🛑 Patients with CUD had a significantly higher risk of death within five years.

🛑 Cannabis use was associated with worse health outcomes, even after adjusting for other factors.

🛑 Findings challenge the assumption that cannabis is a “harmless” substance.

💡 Why This Matters:

As cannabis use becomes more common and legalized, we can’t ignore the potential long-term health consequences—especially in vulnerable populations. This study raises urgent questions about how cannabis impacts physical and mental health in the long run.

📢 What do you think? Should we be taking Cannabis Use Disorder more seriously in medical settings? Drop your thoughts below! 👇

🔗 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829914

#Cannabis #PublicHealth #Addiction #ER #Medicine #addictionmedicine #addiction #cannabisusedisorder #addictionpsychiatry #medical #doctor #medication #marijuana

0

🚨 Cannabis & Brain Function: Short- & Long-Term Effects You NEED to Know 🚨

Cannabis use is everywhere, but do we truly understand its impact on the brain? 🤔 A growing body of research reveals short- and long-term effects that can’t be ignored. Let’s break it down:

🧠 Short-Term Effects
🔹 Impaired memory & attention
🔹 Slower reaction time
🔹 Altered judgment & coordination
🔹 Increased anxiety or paranoia (in some users)

But here’s where it gets even more concerning…

🧠 Long-Term Effects (Especially with frequent or early use)
🔻 Structural brain changes in memory & executive function areas
🔻 Persistent cognitive impairment in heavy users
🔻 Increased risk of psychiatric disorders (psychosis, depression, anxiety)
🔻 Lower IQ in adolescent-onset users

💡 The Takeaway? While cannabis has potential therapeutic uses, chronic or early use can have lasting effects on brain function—especially in young people. Understanding these risks is crucial as legalization expands.

🔬 Have you seen changes in cognition or mental health in cannabis users? Let’s discuss below! 👇 #Cannabis #BrainHealth #Neuroscience #MentalHealth

0

Clearing the Smoke: What We Know About Cannabis for Mental Health Treatment

Research into the therapeutic potential of cannabis for mental health disorders has grown in recent years, with mixed findings from randomized controlled trials (RCTs).

Anxiety Disorders

  • CBD (Cannabidiol) has shown promise in reducing anxiety symptoms in RCTs, particularly for social anxiety disorder (SAD). For instance, a small RCT found that a single dose of 300 mg of CBD reduced anxiety levels in participants undergoing a simulated public speaking test.
  • Some RCTs suggest that CBD may be anxiolytic without causing impairment or euphoria, making it preferable for anxiety compared to THC-dominant cannabis products, which may exacerbate anxiety in some users.

Post-Traumatic Stress Disorder (PTSD)

  • RCTs exploring THC and CBD combinations in PTSD have had mixed outcomes. Some studies indicate that THC may reduce nightmares and improve sleep in PTSD patients, though these findings are generally based on small sample sizes and short-term trials.
  • A recent RCT with a synthetic cannabinoid (nabilone) reported some symptom improvement in PTSD-related insomnia and nightmares. However, larger trials with longer follow-ups are necessary to clarify the efficacy and safety for PTSD.

Depression

  • Few RCTs show consistent evidence supporting cannabis (CBD or THC) as an effective treatment for major depressive disorder. Some trials indicate that CBD may have antidepressant-like effects, possibly due to serotonin receptor activity, but more robust and long-term studies are needed.
  • Concerns persist over THC’s potential to exacerbate depressive symptoms, particularly with regular or heavy use.

Schizophrenia and Psychotic Disorders

  • THC-dominant products have been associated with increased risk of psychosis and exacerbation of symptoms in people predisposed to psychotic disorders. This has led to caution against THC use in people with schizophrenia.
  • CBD has shown promise as an adjunctive treatment in some RCTs, with findings suggesting that it may have antipsychotic effects without the psychoactive effects of THC. For example, an RCT found that CBD reduced psychotic symptoms and improved cognitive function when added to standard antipsychotic treatment, though the effects were modest.

Bipolar Disorder

  • Evidence from RCTs on the use of cannabis in bipolar disorder is sparse and generally negative. Some trials indicate that THC may worsen manic and depressive symptoms in bipolar patients, and there is little to no support for cannabis as a treatment for bipolar depression.

Sleep Disorders

  • Some RCTs have evaluated cannabinoids for sleep disturbances, with CBD showing potential for improving sleep quality. However, THC may reduce REM sleep, which could impact sleep architecture negatively over time.
  • For PTSD-related insomnia, cannabinoids like nabilone have shown some benefit, but the effects on sleep in general populations remain uncertain.

Limitations

  • Sample Sizes and Duration: Many RCTs are small and short-term, limiting the generalizability and understanding of long-term effects.
  • Dosing and Formulations: Variability in cannabinoid content (THC vs. CBD), formulations (edibles, oils, vapes), and dosages across studies makes comparison challenging.
  • Side Effects: Both CBD and THC can have side effects, though THC’s psychoactive properties can lead to cognitive impairment, addiction potential, and negative impact on mood in some patients.

While CBD shows some promise in anxiety, PTSD, and psychotic disorders, RCT evidence for other mental health conditions remains inconclusive or even negative, especially with THC. Further large-scale, long-term RCTs are needed to establish the efficacy and safety profile of cannabis-based treatments in mental health.

0

Powered by WordPress.com.

Up ↑